Company Announcement / Press release Archives - Page 7 of 18

Dasynoc granted Orphan Drug Designation in the US for the treatment of chronic myeloid leukemia

Xspray Pharma (Nasdaq Stockholm: Xspray) today announced that the US Food and Drug Administration (FDA) has granted Dasynoc Orphan Drug Designation (ODD) in the US for the treatment of chronic myeloid leukemia (CML). The FDA decision to grant the designation is based on the plausible hypothesis that Dasynoc may be clinically superior to the same […]

Xspray Pharma appoints Thomas Walz as Chief Medical Officer

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) announces today that the company has appointed Thomas Walz to the newly established position Chief Medical Officer (CMO). Thomas joins Xspray Pharma from a senior role at GSK and will take up the new position in September 2022. “As Xspray Pharma takes steps towards a sharp commercialization phase […]

Xspray Pharma’s long-term incentive program LTI 2022 fully subscribed

Xspray Pharma AB (publ) today announces the outcome of the subscription of options in the incentive program approved at the Annual General Meeting on May 19, 2022. The long-term incentive program 2022 (LTI 2022) in the form of warrants and employee stock options was fully subscribed, in total 421,875 options will be issued. All members […]

Bulletin from the 2022 Annual General Meeting of Xspray Pharma AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Xspray Pharma AB (publ) (“Xspray”) on 19 May 2022. Adoption of income statement and balance sheet for the financial year 2021 and discharge from liabilityThe AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2021 […]

Xspray Pharma – Capital Markets Day Invitation

Xspray Pharma hereby invites investors, analysts, media representatives and other stakeholders to a Capital Markets Day, Tuesday May 24, 2022 at 10.00-12.00 CET, followed by lunch, at Hallvarsson & Halvarson, Sveavägen 20, Stockholm. The Capital Markets Day will be webcast between 10.00-12.00 CET. After the Capital Markets Day an on-demand replay will be available on […]

An eventful quarter sets the agenda for an intense 2022

First Quarter 2022 (January 1 – March 31), Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -18,934 thousand (-13,912) Earnings per share before dilution amounted to SEK -0.92 (-0.73) Cash flow from operating activities amounted to SEK -27,613 thousand (-11,971) Cash flow from investing activities amounted to SEK […]

The Nomination Committee’s proposal for the Board of Directors of Xspray Pharma AB

The Nomination Committee proposes Robert Molander as a new member of the Board of Directors at the Annual General Meeting. The Nomination Committee proposes that members of the Board of Directors Anders Ekblom (Chairman since 2021), Anders Bladh (member since 2021), Maris Hartmanis (member since 2015), Torbjörn Koivisto (member since 2017), Christine Lind (member since […]

Notice of annual general meeting of Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, are summoned to the annual general meeting on Thursday 19 May 2022. Pursuant to temporary legislation, Xspray Pharma’s annual general meeting will be carried out through advance voting (postal voting) only. No meeting with the possibility to attend in person or to be represented by […]

Xspray Pharma publishes its annual report for 2021

“In 2021, we once again confirmed that Xspray Pharma’s unique technology platform can produce amorphous versions of protein kinase inhibitors. Having our processes in place means that we can shorten the development time for new products. I look forward to an intensive and productive 2022, during which Xspray Pharma’s organization will develop and mature, and […]

Update on recent developments regarding Dasynoc

Xspray Pharma AB (publ), (Nasdaq Stockholm: XSPRAY) today announced an update on recent developments regarding Xspray Pharma’s first product, Dasynoc, currently under review by the United States Food & Drug Administration (“FDA”). Bristol Myers Squibb (“BMS”) has filed a lawsuit in the United States District Court for the District of New Jersey against Xspray Pharma […]